Steady Price Appreciation and Market Outperformance
Glenmark Pharmaceuticals closed at ₹2,305.50, up by ₹4.10 or 0.18% as of 08:54 PM on 14-Jul. This increase continues a positive trend, with the stock gaining 1.86% over the past week compared to the Sensex’s decline of 1.44%. Over the last month, Glenmark’s shares have appreciated by 6.09%, significantly outpacing the benchmark’s 2.02% rise. Year-to-date, the stock has surged 13.24%, while the Sensex has fallen by 9.58%, underscoring Glenmark’s resilience amid broader market volatility.
Moreover, the stock has delivered a 3.94% return over the last year, contrasting with the Sensex’s 6.32% decline during the same period. The company’s long-term performance is even more striking, with a three-year return of 228.51%, vastly outperforming the Sensex’s 16.64% gain, and a five-year return of 247.21% compared to the benchmark’s 45.65%. These figures highlight Glenmark’s sustained growth trajectory and strong market positioning.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Technical Strength and Rising Investor Participation
Technically, Glenmark Pharmaceuticals is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day marks, signalling a strong upward momentum. The stock has recorded gains for four consecutive days, accumulating a 3.65% return during this period. Investor participation has also increased, with delivery volumes rising to 3.01 lakh shares on 13 Jul, a 12.83% increase compared to the five-day average. This heightened liquidity supports the stock’s capacity to absorb larger trade sizes, with an estimated tradable value of ₹2.68 crore based on 2% of the five-day average traded value.
Robust Financial Performance Underpinning Investor Confidence
Fundamentally, Glenmark Pharmaceuticals demonstrates a strong financial footing. The company’s ability to service debt is notable, with a low Debt to EBITDA ratio of 0.13 times, indicating minimal leverage risk. Profitability metrics are impressive, with the latest six months’ PAT reaching ₹1,133.97 crore, reflecting a remarkable growth rate of 103.40%. The company’s Return on Capital Employed (ROCE) for the half-year stands at an exceptional 40.16%, while Return on Equity (ROE) is a healthy 26.9%, underscoring efficient capital utilisation and shareholder value creation.
Net sales for the nine-month period have also increased to ₹13,718.08 crore, signalling strong top-line growth. Despite these robust fundamentals, the stock trades at a Price to Book Value of 6.2, which is considered attractive given its historical valuations and peer comparisons. The company’s PEG ratio of 0.2 further suggests that the stock is undervalued relative to its earnings growth, making it an appealing proposition for value-conscious investors.
Thinking about Glenmark Pharma? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this Midcap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Institutional Backing and Market Recognition
Institutional investors hold a significant 39.67% stake in Glenmark Pharmaceuticals, reflecting strong confidence from entities with advanced analytical capabilities. This institutional interest often provides stability and can act as a catalyst for sustained price appreciation. Additionally, the company ranks among the top 1% of all 4,000 stocks rated by MarketsMojo, highlighting its superior fundamentals and consistent performance.
Over the last three years, Glenmark has consistently outperformed the BSE500 index annually, reinforcing its status as a reliable growth stock within the pharmaceutical sector. While the stock slightly underperformed its sector on the day by 0.6%, the broader trend remains positive, supported by solid earnings growth and improving operational metrics.
Conclusion
In summary, Glenmark Pharmaceuticals Ltd.’s recent rise in share price is underpinned by a combination of strong financial results, consistent outperformance against benchmarks, technical strength, and growing investor participation. The company’s robust profitability, low leverage, and attractive valuation metrics have fostered confidence among institutional and retail investors alike. These factors collectively explain the stock’s upward trajectory as of 14-Jul, positioning Glenmark as a compelling midcap pharmaceutical stock in the current market environment.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
